Clinical trials in Rome – page 24

2 209 clinical trials in Rome, Italy across 15 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Rome at a glance

2 209

clinical trials

Research sites15

Quick filters

2 209 trials in Rome

Open in trial search

Acute myeloid leukaemia

Recruiting

Study of Ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

Registered drug

Study of Ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Azacitidine
Sponsor:Kura Oncology Inc.

Contact Research Centre

Autoimmune haemolytic anaemia+1

Recruiting

A study to evaluate the safety and effectiveness of tafasitamab in adults with autoimmune thrombocytopenia or autoimmune hemolytic anemia

Registered drugNo placebo

A study to evaluate the safety and effectiveness of tafasitamab in adults with autoimmune thrombocytopenia or autoimmune hemolytic anemia

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Tafasitamab
Sponsor:Incyte Corp.

Contact Research Centre

Immunoglobulin G4 related disease

Recruiting

A study to evaluate the safety and effects of inebilizumab in children and adolescents with immunoglobulin G4-related disease

Registered drugNo placebo

A study to evaluate the safety and effects of inebilizumab in children and adolescents with immunoglobulin G4-related disease

Registered drugNo placebo

Italy

Participants:0–17 years
Substances:Inebilizumab
Sponsor:Amgen Inc.

Contact Research Centre

Squamous cell carcinoma of lung+6

Recruiting

A study to evaluate the safety and effectiveness of BNT324 and BNT327 in patients with advanced lung cancer

InvestigationalNo placebo

A study to evaluate the safety and effectiveness of BNT324 and BNT327 in patients with advanced lung cancer

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:BNT327
Sponsor:BioNTech SE

Contact Research Centre

Still's disease+1

Recruiting

A study to evaluate the long-term safety of apremilast in children with oral ulcers from Behçet’s disease or juvenile psoriatic arthritis

InvestigationalNo placebo

A study to evaluate the long-term safety of apremilast in children with oral ulcers from Behçet’s disease or juvenile psoriatic arthritis

InvestigationalNo placebo

Italy

Participants:0–17 years · 18–64 years
Substances:Apremilast
Sponsor:Amgen Inc.

Contact Research Centre

Osteogenesis imperfecta

Recruiting

A safety study of romosozumab in children and adolescents with osteogenesis imperfecta

Registered drugNo placebo

A safety study of romosozumab in children and adolescents with osteogenesis imperfecta

Registered drugNo placebo

Italy

Participants:0–17 years
Substances:Romosozumab
Sponsor:Amgen Inc.

Contact Research Centre

Acute leukaemia

Recruiting

A study of Enzomenib in adult patients with relapsed or refractory acute leukemia, including those with MLL rearrangement or NPM1 mutation.

InvestigationalNo placebo

A study of Enzomenib in adult patients with relapsed or refractory acute leukemia, including those with MLL rearrangement or NPM1 mutation.

InvestigationalNo placebo

Italy

Participants:0–17 years · 18–64 years · 65+ years
Sponsor:Sumitomo Pharma America Inc.

Contact Research Centre

Metabolic dysfunction-associated liver disease

Recruiting

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Ly3437943 Sodium
Sponsor:Eli Lilly & Co.

Contact Research Centre

K-ras gene mutation+1

Recruiting

Evaluation of Safety, Pharmacokinetics, and Efficacy of RO7782493 and Panitumumab in Advanced Solid Tumors with KRAS G12D Mutation

Registered drugNo placebo

Evaluation of Safety, Pharmacokinetics, and Efficacy of RO7782493 and Panitumumab in Advanced Solid Tumors with KRAS G12D Mutation

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Panitumumab
Sponsor:Genentech Inc.

Contact Research Centre

Squamous cell carcinoma of the hypopharynx+1

Recruiting

Evaluation of Lymphocyte-Sparing Radiotherapy and All-Trans Retinoic Acid in Lateralized Oropharyngeal, Laryngeal, and Hypopharyngeal Squamous Cell Carcinoma

Registered drugNo placebo

Evaluation of Lymphocyte-Sparing Radiotherapy and All-Trans Retinoic Acid in Lateralized Oropharyngeal, Laryngeal, and Hypopharyngeal Squamous Cell Carcinoma

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Cetuximab
Sponsor:Centre Leon Berard

Contact Research Centre

Systemic lupus erythematosus

Recruiting

Evaluation of Long-Term Safety and Efficacy of Litifilimab in Adults with Active Systemic Lupus Erythematosus: A Phase 3 Multicenter, Randomized, Dose-Blind Study

Investigational

Evaluation of Long-Term Safety and Efficacy of Litifilimab in Adults with Active Systemic Lupus Erythematosus: A Phase 3 Multicenter, Randomized, Dose-Blind Study

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Litifilimab
Sponsor:Biogen Idec Research Limited

Contact Research Centre

Breast cancer metastatic

Recruiting

Phase 1b-2 Study of Elacestrant and Abemaciclib in Patients with Brain Metastases from ER-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo

Phase 1b-2 Study of Elacestrant and Abemaciclib in Patients with Brain Metastases from ER-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Abemaciclib
Sponsor:Stemline Therapeutics Inc.

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 234 cities in Italy

Clinical research in Rome

What the registry says about research in the country

01 Respiratory Diseases

Clinical studies focusing on Idiopathic Pulmonary Fibrosis and COPD, evaluating new therapeutic approaches for improving lung function and reducing disease progression.

Pulmonary function assessment
Disease exacerbation prevention
RSV prevention in high-risk populations

Advanced research includes novel antibody treatments and preventive measures for respiratory infections.

02 Oncology Research

Innovative trials targeting metastatic colorectal cancer, gastric cancer, and acute myeloid leukemia, exploring new treatment combinations and targeted therapies.

Targeted molecular therapies
Combination treatment approaches
Advanced stage cancer management

Studies focus on improving response rates and survival outcomes in various cancer types.

03 Neurological Conditions

Research into Parkinson's disease and acute ischemic stroke, investigating novel therapeutic approaches and neuroprotective strategies.

Early disease intervention
Stroke treatment optimization
Disease-modifying therapies

Studies aim to improve neurological outcomes and patient quality of life.

04 Immunological Disorders

Clinical trials examining Immune Thrombocytopenia and Hidradenitis Suppurativa, testing new therapeutic agents for immune-mediated conditions.

Immune system modulation
Novel biological therapies
Long-term disease management

Research focuses on improving treatment outcomes in challenging immune disorders.

Back to Italy All countries